Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr;2(2):61-9.
doi: 10.4103/2249-4847.116402.

Bilirubin neurotoxicity in preterm infants: risk and prevention

Vinod K Bhutani  1 , Ronald J Wong
Affiliations
Review

Bilirubin neurotoxicity in preterm infants: risk and prevention

Vinod K Bhutani et al. J Clin Neonatol. 2013 Apr.

Abstract

Hemolytic conditions in preterm neonates, including Rhesus (Rh) disease, can lead to mortality and long-term impairments due to bilirubin neurotoxicity. Universal access to Rh immunoprophylaxis, coordinated perinatal-neonatal care, and effective phototherapy has virtually eliminated the risk of kernicterus in many countries. In the absence of jaundice due to isoimmunization and without access to phototherapy or exchange transfusion (in 1955), kernicterus was reported at 10.1%, 5.5%, and 1.2% in babies <30, 31-32, and 33-34 wks gestational age, respectively. Phototherapy initiated at 24±12 hr effectively prevented hyperbilirubinemia in infants <2,000 g even in the presence of hemolysis. This approach (in 1985) reduced exchange transfusions from 23.9% to 4.8%. Now with 3 decades of experience in implementing effective phototherapy, the need for exchange transfusions has virtually been eliminated. However, bilirubin neurotoxicity continues to be associated with prematurity alone. The ability to better predict this risk, other than birthweight and gestation, has been elusive. Objective tests such as total bilirubin, unbound or free bilirubin, albumin levels, and albumin-bilirubin binding, together with observations of concurrent hemolysis, sepsis, and rapid rate of bilirubin rise have been considered, but their individual or combined predictive utility has yet to be refined. The disruptive effects of immaturity, concurrent neonatal disease, cholestasis, use of total parenteral nutrition or drugs that alter bilirubin-binding abilities augment the clinical risk of neurotoxicity. Current management options rely on the "fine-tuning" of each infant's exposure to beneficial antioxidants and avoidance of silent neurotoxic properties of bilirubin navigated within the safe spectrum of operational thresholds demarcated by experts.

Keywords: Bilirubin neurotoxicity; hyperbilirubinemia; jaundice; kernicterus; preterm.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Case history
Figure 2
Figure 2
Kernicterus spectrum disorders in children of preterm birth
Figure 3
Figure 3
Operationalization of phototherapy-based expert recommendations
See this image and copyright information in PMC

References

    1. American Academy of Pediatrics. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297–316. - PubMed
    1. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or = 35 weeks’ gestation: An update with clarifications. Pediatrics. 2009;124:1193–8. - PubMed
    1. Ip S, Lau J, Chung M, Kulig J, Sege R, Glicken S, et al. Hyperbilirubinemia and kernicterus: 50 years later. Pediatrics. 2004;114:263–4. - PubMed
    1. Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol. 2012;32:660–4. - PubMed
    1. Crosse VM, Meyer TC, Gerrard JW. Kernicterus and prematurity. Arch Dis Child. 1955;30:501–8. - PMC - PubMed